Apogee therapeutics announces positive 16-week data from phase 2 apex clinical trial of apg777, its potentially best-in-class anti-il-13 antibody, in moderate-to-severe atopic dermatitis

Apex part a met all primary and key secondary endpoints and exceeded trial objectives, including 7 1.0% decrease from baseline in easi at week 16

APG Ratings Summary

APG Quant Ranking